Groundbreaking Alzheimer’s Disease Blood Test Subject of Upcoming Webinar

Posted May 20, 2021

Cure Alzheimer’s Fund to host conversation with co-creator David M. Holtzman, M.D.

Cure Alzheimer’s Fund will host Dr. David Holtzman for a live webinar on Thursday, May 27 at 5:30 PM.  Diagnosing Alzheimer’s Disease: A Groundbreaking New Blood Test is free and open to the public. Registration is required.

Dr. Holtzman is a co-inventor of a new blood test, PrecivityAD, designed to assist physicians with diagnosing Alzheimer’s disease. The blood test is the first of its kind to measure beta-amyloid protein, the hallmark of Alzheimer’s disease, to accurately indicate whether someone 60 years of age or older who has memory concerns has the classic pathology of Alzheimer’s in their brain. Since a specific Alzheimer’s diagnosis has previously required expensive and often inaccessible PET imaging scans, his discovery has significant implications for use in clinical practice and treatment trials.

“Cure Alzheimer’s Fund is truly privileged to participate in this webinar with Dr. Holtzman.  He is recognized as a giant in Alzheimer’s research and as a caring clinician for the patients he sees,” said Meg Smith, Executive Vice President of Research Management for Cure Alzheimer’s Fund. “As such, he can provide a broad perspective on why this blood test has been so urgently needed and how it will change the patient experience and advance efforts to bring effective treatments to them.” Ms. Smith will moderate the conversation with Dr. Holtzman during the webinar.

Dr. Holtzman, M.D., is the Chair of the Department of Neurology at Washington University School of Medicine in St. Louis and a founding member of the Cure Alzheimer’s Fund Research Leadership Group. His lab has published extensively on the neurobiology of APOE, neuronal activity, glucose, insulin, and the impact of sleep on Alzheimer’s disease.

Cure Alzheimer’s Fund is a non-profit organization that provides grants to the most promising research to prevent, slow or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has contributed $125 million to research. Its funded initiatives have been responsible for several key breakthroughs  – including the groundbreaking “Alzheimer’s in a Dish” study. With 100 percent of donations going directly to research, Cure Alzheimer’s has been able to support some of the best scientific minds in the field of Alzheimer’s research.